Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 20/20 | 1.00 |
| ▸ | CDK2 | P24941 | 20/20 | 1.00 |
| ▸ | CCND1 | P24385 | 18/20 | 1.00 |
| ▸ | CDK6 | Q00534 | 18/20 | 1.00 |
| ▸ | CDK4 | P11802 | 4/20 | 0.68 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.68 |
| ▸ | CDK9 | P50750 | 2/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19863616 | 1.00 | CCNE1 (1.00) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL19863619 | 0.90 | CCNE1 (1.00) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL19863617 | 0.90 | CCNE1 (1.00) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL19863659 | 0.90 | CCNE1 (1.00) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL19863614 | 0.88 | CCNE1 (1.00) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL19863613 | 0.88 | CCNE1 (1.00) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL19868141 | 0.87 | CCNE1 (0.81) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL19868324 | 0.87 | CCNE1 (0.81) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL19857377 | 0.87 | CCNE1 (1.00) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL19863674 | 0.87 | CCNE1 (1.00) | CCNE1CDK2CCND1CDK6CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11396512-B2 | CDK2/4/6 inhibitors | PFIZER INC. (US) | 2022-07-26 | — | — | US | disclosed |
| EP-3497103-B1 | PYRIDOPYRIMDINONE CDK2/4/6 INHIBITORS | PFIZER (US) | 2021-05-05 | — | — | EP | disclosed |
| US-20200392142-A1 | CDK2/4/6 Inhibitors | PFIZER INC. (US) | 2020-12-17 | — | — | US | disclosed |
| US-10800783-B2 | CDK2/4/6 inhibitors | PFIZER INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-20190135817-A1 | CDK2/4/6 Inhibitors | PFIZER INC. (US) | 2019-05-09 | — | — | US | disclosed |
| US-10233188-B2 | CDK2/4/6 inhibitors | PFIZER INC. (US) | 2019-03-19 | — | — | US | disclosed |
| WO-2018033815-A1 | PYRIDOPYRIMDINONE CDK2/4/6 INHIBITORS | PFIZER INC. (US) | 2018-02-22 | — | — | WO | disclosed |
| US-20180044344-A1 | CDK2/4/6 Inhibitors | PFIZER INC. (US) | 2018-02-15 | — | — | US | disclosed |
| US-20180044344-A1 | CDK2/4/6 Inhibitors | PFIZER INC. (US) | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392142-A1 | CDK2/4/6 Inhibitors | CDK2, CDK6, CDK20 | CCNE1 28/4885CDK2 1/4885CCND1 39/4885 |
| US-11396512-B2 | CDK2/4/6 inhibitors | CDK2, CDK6, CDK20 | CCNE1 29/4885CDK2 1/4885CCND1 40/4885 |
| US-10800783-B2 | CDK2/4/6 inhibitors | CDK2, CDK6, CDK20 | CCNE1 29/4885CDK2 1/4885CCND1 40/4885 |
| US-20180044344-A1 | CDK2/4/6 Inhibitors | CDK2, CDK6, CDK20 | CCNE1 29/4885CDK2 1/4885CCND1 40/4885 |
| US-20190135817-A1 | CDK2/4/6 Inhibitors | CDK2, CDK6, CDK20 | CCNE1 29/4885CDK2 1/4885CCND1 40/4885 |
| US-10233188-B2 | CDK2/4/6 inhibitors | CDK2, CDK6, CDK20 | CCNE1 29/4885CDK2 1/4885CCND1 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.